BML-277

CAS No. 516480-79-8

BML-277( BML-277 | C 3742 | Checkpoint Kinase 2 Inhibitor II )

Catalog No. M14798 CAS No. 516480-79-8

BML-277 (C 3742) is a selective Chk2 (checkpoint kinase 2) inhibitor with an IC50 of 15 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 42 In Stock
10MG 69 In Stock
25MG 143 In Stock
50MG 285 In Stock
100MG 426 In Stock
500MG 888 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    BML-277
  • Note
    Research use only, not for human use.
  • Brief Description
    BML-277 (C 3742) is a selective Chk2 (checkpoint kinase 2) inhibitor with an IC50 of 15 nM.
  • Description
    BML-277 (C 3742) is a selective Chk2 (checkpoint kinase 2) inhibitor with an IC50 of 15 nM.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    BML-277 | C 3742 | Checkpoint Kinase 2 Inhibitor II
  • Pathway
    Angiogenesis
  • Target
    Chk
  • Recptor
    Chk2
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    516480-79-8
  • Formula Weight
    363.8
  • Molecular Formula
    C20H14ClN3O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 10 mM
  • SMILES
    O=C(C1=CC=C2C(N=C(C3=CC=C(OC4=CC=C(Cl)C=C4)C=C3)N2)=C1)N
  • Chemical Name
    2-(4-(4-Chlorophenoxy)phenyl)-1H-benzimidazole-5-carboxamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Arienti KL, et al. J Med Chem. 2005 Mar 24; 48(6): 1873-85.
molnova catalog
related products
  • VER-158411

    A potent, selective, ATP-competitive Chk1 and Chk2 inhibitor with IC50 of 4.4 nM and 4.5 nM, respectively.

  • BAY-1816032

    BAY-1816032 (BAY1816032) is a highly potent, selective, orally active BUB1 mitotic checkpoint serine/threonine kinase with IC50 of 7 nM.

  • GDC0575 monohydrochl...

    GDC-0575 is a potent and selective inhibitor of cell cycle checkpoint kinase 1 (Chk1) with an IC50 of 1.2?nM. GDC-0575 specifically binds to and inhibits Chk1; this may result in tumor cells bypassing Chk1-dependent cell cycle arrest in the S and G2/M phases, which permits the cells to undergo DNA repair prior to entry into mitosis.